Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally
BillionToOne wins upbeat coverage as analysts flag growth in prenatal, cancer tests
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Molecular diagnostics firm BillionToOne raises $273 million in US IPO